2021 – Trefoil therapeutics

Year: 2021

December 1, 2021

Trefoil Therapeutics Announces Third Tranche of $28 Million Series A Financing Based on Achievement of Clinical Trial Objectives

San Diego, CA, December 1, 2021 – Trefoil Therapeutics today announced that after review of the interim clinical data from the INTREPID and STORM studies, the Series A investors have funded the third tranche of its $28 million Series A

March 10, 2021

Price Vision Group Participating in Clinical Study of Investigational Growth Factor Treatment for Eye Disorder, Fuchs Endothelial Corneal Dystrophy

Indianapolis, IN – March 10, 2021 – Price Vision Group announced today that it is the first site to initiate patient treatment in a clinical trial evaluating use of an experimental drug treatment in conjunction with a surgical procedure that

February 9, 2021

Trefoil Therapeutics Begins Second Phase 2 “STORM” Clinical Trial with Regenerative Treatment for Fuchs Endothelial Corneal Dystrophy

Study evaluating engineered FGF-1’s (TTHX114) potential in patients undergoing Descemet Stripping Only (DSO or DWEK) procedures San Diego, CA – February 9, 2021 – Trefoil Therapeutics today announced it has begun a Phase 2 clinical trial of its engineered Fibroblast